Loading…
Contineum Therapeutics, Inc. is projected to rise to $16.36 by 2027, a +8% move from its current price of $15.19. CTNM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $14.62 | $15.19 | $15.78 | -0.03% |
| Jul 13 | $14.38 | $15.18 | $16.02 | -0.07% |
| Jul 14 | $14.20 | $15.18 | $16.21 | -0.10% |
| Jul 15 | $14.05 | $15.17 | $16.38 | -0.13% |
| Jul 16 | $13.92 | $15.17 | $16.52 | -0.16% |
| Jul 17 | $13.80 | $15.16 | $16.65 | -0.20% |
| Jul 18 | $13.70 | $15.16 | $16.77 | -0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.70 | $15.16 | $16.77 | -0.23% |
| Week 2 | $13.10 | $15.12 | $17.45 | -0.46% |
| Week 3 | $12.66 | $15.09 | $17.97 | -0.69% |
| Week 4 | $12.29 | $15.05 | $18.43 | -0.92% |
| Week 5 | $11.98 | $15.02 | $18.83 | -1.14% |
| Week 6 | $11.69 | $14.98 | $19.20 | -1.37% |
| Week 7 | $11.44 | $14.95 | $19.54 | -1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing small molecules for neuroscience, inflammation, and immunology indications in the United States.
Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
It also develops PIPE-307, a novel small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc.
in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
CTNM is currently priced at $15.24 per share, with a market cap of $569.77M and a rank of 2974.
The forecast landscape shows a progression in average prices across years, with 2026 average listed at $15.24 and a path toward higher values in later years. Key long-range figures include a 2030 average of $20.61 and a 2050 average of $90.40, with a 2050 maximum of $195.09 and a 2030 maximum of $32.73.
The forecast also provides a pattern of rising values over time, where 2030 remains a turning point toward stronger upside, and the later years project substantial appreciation relative to today’s levels.
A major floor 39.4% below — a decisive break under it would weaken the trend.
The nearest floor, 25.6% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 27.6% above — clearing it would confirm fresh momentum.
Key CTNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.28 | Sell | $15.24 | Sell |
| MA 10 | $15.23 | Sell | $14.89 | Buy |
| MA 20 | $13.75 | Buy | $14.23 | Buy |
| MA 50 | $13.45 | Buy | $13.61 | Buy |
| MA 100 | $13.54 | Buy | $13.26 | Buy |
| MA 200 | $12.68 | Buy | $12.51 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.63 | Neutral |
| Stoch RSI (14) | 54.01 | Neutral |
| CCI (20) | 64.87 | Neutral |
| Williams %R (14) | -25.16 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 27.54 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 74.84 | Neutral |
| TRIX (15) | 0.57 | Buy |
| Awesome (5,34) | 1.95 | Buy |
| Ultimate (7,14,28) | 47.76 | Neutral |
| Momentum (10) | 1.83 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 15.31 | Sell |
| ADX (14) | 20.33 | Buy |
| ATR (14) | 0.55 | Info |
The 30-day technical picture is bullish in sentiment terms. RSI14 is 60, indicating room above oversold levels but not extreme overbought conditions.
The simple moving averages show SMA50 at $13.14 and SMA200 at $12.59, suggesting the near-term trend is upward relative to common baseline levels. Support is identified at $11.30 and resistance at $16.39, marking a traditional range for price action.
The 30-day price range spans from a low of $11.74 to a high of $19.78, illustrating notable near-term volatility within a constructive direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.17 | $15.19 | $18.63 | 0% | Neutral | |
| $12.54 | $16.36 | $22.85 | +8% | Neutral | |
| $11.27 | $15.32 | $22.46 | +1% | Neutral | |
| $11.20 | $15.76 | $24.00 | +4% | Neutral | |
| $14.11 | $20.46 | $32.17 | +35% | Bullish | |
| $15.79 | $23.54 | $38.05 | +55% | Bullish | |
| $17.43 | $26.69 | $44.20 | +76% | Bullish | |
| $17.15 | $26.94 | $45.60 | +77% | Bullish | |
| $15.22 | $24.48 | $42.28 | +61% | Bullish | |
| $17.27 | $28.42 | $50.01 | +87% | Bullish | |
| $22.47 | $41.18 | $78.30 | +171% | Bullish | |
| $39.32 | $87.37 | $185.60 | +475% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.17 | $15.19 | $17.74 | +0.00% |
| August 2026 | $12.17 | $14.53 | $17.92 | -4.35% |
| September 2026 | $12.23 | $14.74 | $18.46 | +1.46% |
| October 2026 | $11.74 | $14.28 | $18.11 | -3.16% |
| November 2026 | $11.30 | $13.84 | $17.74 | -3.05% |
| December 2026 | $11.67 | $14.39 | $18.63 | +3.97% |
Click any year to see its month-by-month CTNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Contineum Therapeutics, Inc.'s 2026 outlook centres on $15.19, within a $9.17 to $18.63 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CTNM could reach as high as $22.85, with a base case around $16.36 and support toward $12.54 — roughly +8% from $15.19. Price action looks broadly range-bound.
Expect CTNM to range from $11.27 to $22.46 through 2028. The $15.32 average target implies a +1% move from current prices. That is -6% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The CTNM price prediction for 2029 points to an average of $15.76 (low $11.20, high $24.00) — a potential gain of +4% on today's $15.19. Price action looks broadly range-bound.
In 2030, CTNM is projected to trade between $14.11 and $32.17, averaging $20.46 — a potential gain of +35% from today's $15.19. That is up +30% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Contineum Therapeutics, Inc.'s 2031 outlook centres on $23.54, within a $15.79 to $38.05 range. That is up +15% on the projected 2030 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2032, CTNM could reach as high as $44.20, with a base case around $26.69 and support toward $17.43 — roughly +76% from $15.19. Buyers look set to stay in control over this stretch.
Expect CTNM to range from $17.15 to $45.60 through 2033. The $26.94 average target implies a +77% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The CTNM price prediction for 2034 points to an average of $24.48 (low $15.22, high $42.28) — a potential gain of +61% on today's $15.19. Buyers look set to stay in control over this stretch.
In 2035, CTNM is projected to trade between $17.27 and $50.01, averaging $28.42 — a potential gain of +87% from today's $15.19. That is up +16% on the projected 2034 average. Momentum favours further upside here.
Contineum Therapeutics, Inc.'s 2040 outlook centres on $41.18, within a $22.47 to $78.30 range. That is up +45% on the projected 2035 average. That marks a +171% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CTNM could reach as high as $185.60, with a base case around $87.37 and support toward $39.32 — roughly +475% from $15.19. Momentum favours further upside here.
Investing $1,000 in CTNM today (≈ 65.832785 CTNM) could be worth
$5,752.02
+$4,752.02 (+475%) by 2050 · US Dollar
Based on the average projected CTNM price of $87.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTNMwould be worth at today's price.
$1,000 invested in CTNM on Jul 10, 2025 (≈ 248.138945 CTNM) would be worth
$3,769.23
+$2,769.23 (+276.9%) today · 3.77× · US Dollar
Based on a CTNM entry price of $4.03 vs. today's $15.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.1 | $1,005.96 | +0.6% |
| 1 month ago | $11.3 | $1,344.25 | +34.4% |
| 3 months ago | $12.87 | $1,180.26 | +18.0% |
| 6 months ago | $9.17 | $1,656.49 | +65.6% |
| 1 year ago | $4.03 | $3,769.23 | +276.9% |
| All time (2.3y) ago | $15.4 | $986.36 | -1.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTNM forecast.
Our base-case forecast reaches $30.00 around 2040.
Implied market cap at $30.00: $981.72M
The multi-year outlook is bullish from 2030 onward. The 2030 forecast shows an average of $20.61, with a min of $14.08 and a max of $32.73, and a forecasted ROI of 35.3%.
In 2031 the average rises to $23.96 with a max of $39.13 and a min of $15.89, delivering an ROI of 57.2% in that year.
2032 is projected at an average of $27.10 (min $17.48, max $45.38) with an ROI of 77.8%; 2033 at an average of $26.92 (min $16.91, max $46.09) with an ROI of 76.6%; 2034 at an average of $24.71 (min $15.14, max $43.20) with an ROI of 62.2%; and 2035 at an average of $29.02 (min $17.36, max $51.70) with an ROI of 90.4%.
Looking further out, 2040 is forecast at an average of $41.40 (min $22.11, max $79.82) with an ROI of 171.7%, and 2050 at an average of $90.40 (min $40.68, max $195.09) with an ROI of 493.2%.
These figures point to a longer-term bullish trajectory, but the outlook carries inherent uncertainty and should be treated as estimates rather than guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $20.61 with a min of $14.08 and a max of $32.73, and a forecasted ROI of 35.3%.
Forecasts show rising averages in the longer term, including 2031 with an average of $23.96 (ROI 57.2%), 2032 with an average of $27.10 (ROI 77.8%), 2035 with an average of $29.02 (ROI 90.4%), and 2050 with an average of $90.40 (ROI 493.2%). Earlier years (2026–2029) show neutral sentiment with limited or no ROI in those specific years.
Among the year-by-year forecasts, the 2030 max is $32.73 and the 2035 max is $51.70, so reaching $50 is not projected by 2030 and is only possible by 2035 within the given max values.
Current price is $15.24 and the 30-day range spans from $11.74 to $19.78.
CTNM has a market cap of $569.77M and a rank of 2974.
Contineum Therapeutics, Inc. Community Discussion
0Share your Contineum Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.